meta_analysis
    2017
    High Quality

    Silymarin in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials

    Zhong S, Fan Y, Yan Q

    Published in Medicine

    Key Findings

    Silymarin significantly reduced serum ALT and AST in patients with non-alcoholic fatty liver disease.

    Conclusions

    Enzyme improvement without hard outcome data.

    Limitations

    Surrogate endpoints, mostly small trials.

    Supplements Studied

    Silymarin significantly reduced serum ALT and AST in patients with non-alcoholic fatty liver disease.

    Outcomes Measured

    Liver Protection

    Silymarin reduced serum ALT and AST in fatty liver disease.

    Related Health Concerns

    Non-Alcoholic Fatty Liver Disease

    Study Details

    Year:2017
    Sample Size:587
    Quality Score:7/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.